evenamide evenamide evenamide (inn) (developmental code names nw-3509, nw-3509a) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes nav1.3, nav1.7, and nav1.8, which is described as an antipsychotic and is under development by newron pharmaceuticals as an add-on therapy for the treatment of schizophrenia. the drug has shown efficacy in animal models of psychosis, mania, depression, and aggression. it has completed phase i clinical trials, and phase ii clinical trials will be commenced in the third quarter of 2015. evenamideclinical dataother namesnw-3509; nw-3509aatc codenoneidentifiers iupac name 2--n,n-dimethylacetamide cas number1092977-61-1 ypubchem cid25105689chemspider44208827uniion5s6n53jschemical and physical dataformulac16h26n2o2molar mass278.396 g·mol−13d model (jsmol)interactive image smiles ccccoc1cccc(ccncc(=o)n(c)c)c1 inchi inchi=1s/c16h26n2o2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17h,4-5,9-11,13h2,1-3h3key:grhbodilppxvkn-uhfffaoysa-n